



EXPRESS MAIL NO.: EV 452 774 381 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kunz et al. Confirmation No.: 1690
Application No.: 09/910,388 Art Unit: 1653
Filed: July 20, 2001 Examiner: Robinson, Hope A.
For: THERAPEUTIC INHIBITOR Attorney Docket No.: 10177-211-999
OF VASCULAR SMOOTH (CAM 008563-999208)
MUSCLE CELLS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the United States Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be related to patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references A01-A08, B01-B79 and C01-C184 listed on the accompanying List of References Cited by Applicants. Copies of references A01-A08 and B01-B74 are submitted herewith. Copies of references B75-B79, C01 and C03-C184 are being concurrently submitted under separate cover with Express Mail No. EV 452 773 871 US.

The above-identified application claims priority under 35 U.S.C. § 120 to U.S. Patent Application No. 09/113,733 ("the '733 application"), filed July 10, 1998, now U.S. Patent No. 6,074,659, issued June 13, 2000. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of the '626 application for copies of reference C02.

References B01-B06, B08, B12-B15, B18, B22-B27, B34-B37, B39-B41, B42-B45, B47-B49, B51, B53-B72, B74-B79, C01-C11, C13-C31, C33, C36-C45, C47-C70, C73-C76,

C78-C88, C90-C103, C105-C118, C120-C127, C129-C163, C165-C171 and C173-C184 were previously cited in the Information Disclosure Statement filed on July 20, 2001, the Supplemental Information Disclosure Statement filed on January 25, 2002, the Supplemental Information Disclosure Statement filed on March 25, 2002, and the Supplemental Information Disclosure Statement filed on June 26, 2002 and are allegedly missing from the files of the application. References A01-A08, B07, B09-B11, B16-B17, B19-B21, B28-B33, B38, B42, B46, B50, B52, B73, C12, C32, C34-C35, C46, C71-C72, C77, C89, C104, C119, C128, C164 and C172 were recently brought to the attention of Attorneys for Applicants.


Identification of the above-listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.


Pursuant to 37 CFR § 1.97(b), since this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, it is believed that no fee is due in connection herewith. However, should the United States Patent and Trademark Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,


Date: November 22, 2004


Gidon D. Stern 27,469
(Reg. No.)

By:


Catharina J. Chin Eng 42,412
(Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939


Enclosures

**LIST OF REFERENCES CITED BY APPLICANTS**
(Use several sheets if necessary)ATTY DOCKET NO.
10177-211-999
(Cam No. 008563-999208)APPLICATION NO
09/910,388APPLICANT
Kunz et al.FILING DATE
July 20, 2001GROUP
1653**U.S. PATENT DOCUMENTS**


*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,391,797	07/05/83	Folkman et al.			
	A02	4,768,507	09/06/88	Fischell et al.			
	A03	5,019,096	05/28/91	Fox et al.			
	A04	5,474,563	12/12/95	Myler et al.			
	A05	5,512,055	04/30/96	Domb et al.			
	A06	5,567,417	10/22/96	Sasisekharan et al.			
	A07	5,616,608	04/01/97	Kinsella et al.			
	A08	6,403,635 B1	06/11/02	Kinsella et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	EP 0 260 066	03/16/88	European				
	B02	EP 0 297 946	01/04/89	European				
	B03	EP 0 365 863	05/02/90	European				
	B04	EP 0 374 044	06/20/90	European				
	B05	EP 0 411 893	02/06/91	European				
	B06	EP 0 451 202	10/16/91	European				
	B07	EP 0 470 569 A1	08/06/91	European				
	B08	EP 0 526 102	02/03/93	European				
	B09	EP 0 543 653 A1	05/26/93	European				
	B10	EP 0 567 816 A1	04/08/93	European				
	B11	EP 0 568 310 A1	04/27/93	European				
	B12	EP 0 577 215	01/05/93	European				
	B13	EP 0 588 518	03/23/94	European				
	B14	EP 0 606 613	07/20/94	European				
	B15	EP 0 622 076	11/02/94	European				
	B16	EP 0 623 354 A1	11/09/94	European				
	B17	EP 0 623 354 B1	10/02/02	European				
	B18	EP 0 691 130	01/10/96	European				
	B19	EP 0 711 158 B1	12/03/03	European				
	B20	EP 1 181 943 A1	02/27/02	European				
	B21	WO 85/00107	01/17/85	PCT				
	B22	WO 88/10259	12/29/88	PCT				



B23	WO 90/01969	03/08/90	PCT				
B24	WO 90/11676	10/18/90	PCT				
B25	WO 90/12597	11/01/90	PCT				
B26	WO 90/13293	11/15/90	PCT				
B27	WO 90/13332	11/15/90	PCT				
B28	WO 91/07154	05/30/91	PCT				
B29	WO 91/10424	07/25/91	PCT				
B30	WO 91/11193	08/08/91	PCT				
B31	WO 91/12779	09/05/91	PCT				
B32	WO 91/12846	09/05/91	PCT				
B33	WO 91/15219	10/14/91	PCT				
B34	WO 91/15222	10/17/91	PCT				
B35	WO 91/17731	11/28/91	PCT				
B36	WO 92/08480	05/29/92	PCT				
B37	WO 92/10210	06/25/92	PCT				
B38	WO 92/11872	07/23/92	PCT				
B39	WO 92/11890	07/23/92	PCT				
B40	WO 92/11895	07/23/92	PCT				
B41	WO 92/12717	08/06/92	PCT				
B42	WO 92/15286	02/21/02	PCT				
B43	WO 92/18546	10/29/92	PCT				
B44	WO 92/19273	11/12/92	PCT				
B45	WO 92/21363	12/10/92	PCT				
B46	WO 93/06792	04/15/93	PCT				
B47	WO 93/07748	04/29/93	PCT				
B48	WO 93/09790	05/27/93	PCT				
B49	WO 93/11120	06/10/93	PCT				
B50	WO 93/16687	09/02/93	PCT				
B51	WO 93/17121	09/02/93	PCT				
B52	WO 93/17669	09/16/93	PCT				
B53	WO 93/24476	12/09/93	PCT				
B54	WO 94/03644	02/17/94	PCT				
B55	WO 94/04164	03/03/94	PCT				
B56	WO 94/04178	03/03/94	PCT				
B57	WO 94/07529	04/14/94	PCT				
B58	WO 94/08604	04/28/94	PCT				
B59	WO 94/08605	04/28/94	PCT				
B60	WO 94/15590	07/21/94	PCT				
B61	WO 94/15646	07/21/94	PCT				
B62	WO 94/16706	08/04/94	PCT				
B63	WO 94/17786	08/18/94	PCT				
B64	WO 94/18345	08/18/94	PCT				
B65	WO 94/18954	09/01/94	PCT				
B66	WO 94/18967	09/01/94	PCT				
B67	WO 94/18968	09/01/04	PCT				



B68	WO 94/19000	09/01/94	PCT				
B69	WO 94/19001	09/01/94	PCT				
B70	WO 94/19003	09/01/94	PCT				
B71	WO 94/20096	09/25/94	PCT				
B72	WO 94/20097	09/15/94	PCT				
B73	WO 94/21308	09/29/94	PCT				
B74	WO 94/21679	09/29/94	PCT				
B75	WO 94/22436	10/13/94	PCT				
B76	WO 94/25020	11/10/94	PCT				
B77	WO 94/28721	12/22/94	PCT				
B78	WO 95/03036	02/02/95	PCT				
B79	WO 95/03795	02/02/95	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)


C01	"Cytochalasins", In: The Merck Index, Eleventh Edition, Merck & Co., Rahway NJ, 438-439 (1989).						
C02	"Nolvadex Tamoxifene Citrate", ICI Pharma, 64033-02, Rev L/07/92						
C03	Allemann, <i>et al.</i> , "Drug Loaded Poly(Lactic Acid) Nanoparticles Produced by a Reversible Salting-out Process: Purification of an Injectable Dosage Form," <i>Eur. J. Pharm. Biopharm.</i> , Vol. 39 (1), pp. 13-18 (1993)						
C04	Anderson, <i>et al.</i> , "Effects of Acetate Dialysate on Transforming Growth Factor β_1 , Interleukin, and β_2 -Microglobulin Plasma Levels," <i>Kidney International</i> , Vol. 40, pp. 1110-1117 (1991)						
C05	Aschermann, M., "Restenosis After Percutaneous Transluminal Coronary Angioplasty Pathophysiology, New Trends in Prevention and Treatment," <i>Cor. Vasa.</i> , 36:211-218 (1994)						
C06	Assoian, <i>et al.</i> , "Type β Transforming Growth Factor in Human Platelets: Release During Platelet Degranulation and Action on Vascular Smooth Muscle Cells," <i>The Journal of Cell Biology</i> , Vol. 102, pp. 1217-1223 (1986)						
C07	Attwood, <i>et al.</i> , "A Light Scattering Study on Oil-in-Water Microemulsions" <i>Int'l J. Pharm.</i> , 52 165-171 (1989)						
C08	Bagdade, <i>et al.</i> , "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition," <i>J. of Clinical Endocrinology and Metabolism</i> , Vol. 70, No. 4, pp. 1132-35 (1990)						
C09	Bamburg, James R., "Biological and Biochemical Actions of Trichothecene Mycotoxins," <i>Progress in Molecular and Subcellular Biology</i> , (Hahn F.E., <i>et al.</i> , ed.), Springer-Verlag, pp. 41-110 (1983)						
C10	Barath, <i>et al.</i> , "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury," <i>JACC</i> , Vol. 13, No. 2, p. 252A Abstract (1989)						
C11	Barbacid, <i>et al.</i> , "Binding of [acetyl- ¹⁴ C] Trichodermin to the Peptidyl Transferase Center of Eukaryotic Ribosomes," <i>Eur. J. Biochem.</i> 44, pp. 437-444 (1974)						
C12	Bartoli <i>et al.</i> "In vitro and in vivo antitumoral activity of free, and encapsulated taxol". <i>J. Microencapsulation</i> , 7 (2):191-197, 1990						
C13	Beck, <i>et al.</i> , "Poly(DL-Lactide-co-glycolide) /Norethisterone Microcapsules: An Injectable Biodegradable Contraceptive," <i>Biology of Reproduction</i> , Vol. 28, pp. 186-195 (1983)						
C14	Bertelli, <i>et al.</i> , "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels," <i>Breast Cancer Res. and Treatment</i> , Vol. 12, pp. 307-310 (1988)						
C15	Bogyo, <i>et al.</i> , "Cytochalasin- β -Induced Immunosuppression of Murine Allogeneic Anti-tumor Response and the Effect of Recombinant Human Interleukin-2," <i>Cancer Immunol. Immunother.</i> , Vol. 32, pp. 400-405 (1991)						
C16	Bousquet, <i>et al.</i> , "Effects of Cytochalasin β in Culture and <i>in Vivo</i> on Murine Madison 109 Lung Carcinoma and on B16 Melanoma," <i>Cancer Res.</i> , Vol. 50, pp. 1431-39 (1990)						
C17	Bruengger, <i>et al.</i> , "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs," <i>J. Urol.</i> Vol. 130, No. 6, pp. 1208-10 (1983)						
C18	Bruning, <i>et al.</i> , "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", <i>Br. J. Cancer</i> , 58, 497-499 (1988)						
C19	Bumol, <i>et al.</i> , "Unique Glycoprotein-Proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells," <i>PNAS (USA)</i> , Vol. 79, pp. 1245-49 (1982)						
C20	Butta, <i>et al.</i> , "Induction of Transforming Growth Factor β_1 in Human Breast Cancer <i>in vivo</i> Following Tamoxifen Treatment," <i>Cancer Res.</i> Vol. 52, pp. 4261-64 (1992)						
C21	Casscells, W., <i>et al.</i> , "Elimination of Smooth Muscle Cells in Experimental Restenosis: Targeting of Fibroblast Growth Factor Receptors", <i>Proc. Natl. Acad. Sci. USA</i> , 89, 7159-7163 (1992)						
C22	Chaldakov, <i>et al.</i> , "Cyclic AMP-and Cytochalasin B-induced Arborization in Cultured Aortic Smooth Muscle Cells: Its Cytopharmacological Characterization," <i>Cell Tissue Res.</i> Vol. 255, pp. 435-442 (1989)						




C23	Chander, <i>et al.</i> , "Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer," <i>Cancer Research</i> , Vol. 51, pp. 5851-5858 (1991)
C24	Chander, <i>et al.</i> , "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome," <i>Cytokine</i> , Vol. 3, No. 4, pp. 292-298 (1991)
C25	Chapman, <i>et al.</i> , "A Bioabsorbable Stent: Initial Experimental Results," <i>Supplement III Cir.</i> , Vol. 82, No. 4, p. III-72 (1990)
C26	Clowes <i>et al.</i> , "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery," <i>Cir. Res.</i> Vol. 56, No. 1, pp. 139-145 (1985)
C27	Clowes, <i>et al.</i> "Mechanisms of Stenosis After Arterial Injury", <i>Laboratory Investigation</i> , Vol. 49, No. 2, pp. 208-215 (1983)
C28	Clowes, <i>et al.</i> , "Kinetics of Cellular Proliferation After Arterial Injury - I. Smooth Muscle Growth in the Absence of Endothelium", <i>Laboratory Investigation</i> , Vol. 49, No. 3, pp. 327-333 (1983)
C29	Clowes, <i>et al.</i> , "Kinetics of Cellular Proliferation After Arterial Injury - III, Endothelial and Smooth Muscle Growth in Chronically Denuded Vessels", <i>Laboratory Investigation</i> , Vol. 54, No. 3, pp. 295-303 (1986)
C30	Cohen, <i>et al.</i> , "Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres," <i>Pharmaceutical Research</i> , Vol. 8, No. 6, pp. 713-720 (1991)
C31	Cole, R. J. <i>et al.</i> , "The Cytochalasins", In: <i>Handbook of Toxic Fungal Metabolics</i> , Academic Press, New York, p. 264-265, 281-282 (1981)
C32	Coomber and Gottlieb "In vitro endothelial wound repair. Interaction of cell migration and proliferation". <i>Atherosclerosis</i> , 10 (2):215-222, 1990
C33	Cowsar, <i>et al.</i> , "Poly(Lactide-co-glycolide) Microcapsules for Controlled Release of Steroids," <i>Methods in Enzymology</i> , Vol. 112, pp. 101-117 (1985)
C34	Cox <i>et al.</i> , "Effects of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries". <i>Coronary Artery Disease</i> , 3:237-248, 1992
C35	Cox <i>et al.</i> , "Local Delivery of Heparin and methotrexate fails to inhibit in vivo smooth muscle cell proliferation". <i>Circulation Suppl.</i> 84(4):II-71, #0284, 1991
C36	Crissman, <i>et al.</i> , "Transformed Mammalian Cells are Deficient in Kinase-Mediated Control of Progression Through the G ₁ Phase of the Cell Cycle," <i>PNAS (USA)</i> , Vol. 88, pp. 7580-84 (1991)
C37	Danielpour, David, "Improved Sandwich Enzyme-Linked Immunosorbent Assays for Transforming Growth Factor," <i>Journal of Immunological Methods</i> , Vol. 158, pp. 17-25 (1993)
C38	Danielpour, <i>et al.</i> , "Evidence for Differential Regulator of TGFβ1 and TGFβ2 Expression <i>in Vivo</i> by Sandwich Enzyme-linked Immunosorbent Assays," <i>Annals New York Academy of Sciences</i> , pp. 300-302
C39	Danielpour, <i>et al.</i> , "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta (TGF-1 and TGF-2) Secreted by Cells in Culture," <i>Journal of Cellular Physiology</i> , Vol. 138, pp. 79-86 (1989)
C40	Dasch, <i>et al.</i> , "Capture Immunoassays Specific for TGF1 and TGF2: Use in Pharmacokinetic Studies," <i>Annals New York Academy of Sciences</i> , pp. 303-305
C41	Detre, <i>et al.</i> , "Percutaneous Transluminal Coronary Angioplasty in 1985-1986 and 1977-1981", <i>The New England J. of Med.</i> , Vol 318, No. 5, pp. 265-270 (1988)
C42	Dimond, Patricia F., Ph.D., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes," <i>Genetic Engineering News</i> , pp. 7 & 19 (1993)
C43	Ebner, <i>et al.</i> , "Cloning of a Type I TGF-β Receptor and Its Effect on TGF-β Binding to the Type II Receptor," <i>Science</i> , Vol. 260, pp. 1344-48 (1993)
C44	Eldridge, <i>et al.</i> , "Biodegradable and Biocompatible Poly(DL-Lactide-CO-Glycolide) Microspheres as an Adjuvant for Staphylococcal Enterotoxin B Toxoid which Enhances the Level of Toxin-Neutralizing Antibodies," <i>Infection and Immunity</i> , 59(9):2978-2986 (1991)
C45	Epstein, Stephen E., MD., "Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating Vascular Smooth Muscle Cells," <i>Cir.</i> Vol. 84, No. 2, pp. 778-787 (1991)
C46	Ettenson and Gottlieb "Centrosomes, Microtubules, and Microfilaments in the Reendothelialization and Remodeling of Double-Sided In Vitro Wounds". <i>Laboratory Investigation</i> , Vol. 68, No. 6, pp. 722-733, 1992, United States and Canadian Academy of Pathology, Inc.
C47	Fanelli, <i>et al.</i> , "Restenosis Following Coronary Angioplasty", <i>Amer. Heart J.</i> , Vol 119, No. 2, Part 1, pp. 357-368 (1990)
C48	Farhat, <i>et al.</i> , "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium," <i>Br. J. Pharmacol.</i> Vol. 107, pp. 679-683 (1992)
C49	Faxon <i>et al.</i> , "Restenosis Following Transluminal Angioplasty in Experimental Atherosclerosis", <i>Arteriosclerosis</i> , Vol. 4, No. 3, pp. 189-195 (1984)
C50	Fay, <i>et al.</i> , "Effects of Cytochalasin-B On The Uptake of Ascorbic Acid and Glucose By 3T3 Fibroblasts: Mechanism of Impaired Ascorbate Transport in Diabetes," <i>Life Sci.</i> , Vol. 46, pp. 619-624 (1990) (USA)
C51	Feelisch, <i>et al.</i> , "Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and Endothelial Cells," <i>Biochemical and Biophysical Research Communications</i> , Vol. 180, No. 1, pp. 286-293 (1991)

OIP
NOV 22 2004

C52	Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis Experimental and Molecular Pathology", <i>Exp. Mol. Pathol.</i> , 43 288-296 (1985)
C53	Forrester, J.S., et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies: JACC, 17, 758-769, (1991)
C54	Friberg, et al., "Microemulsions and Solubilization by Nonionic Surfactants", <i>Prog. Colloid and Polymer Sci.</i> , 56, 16-20 (1975)
C55	Fulop, et al., "Age-Dependent Variations of Intralysosomal Enzyme Release from Human PMN Leukocytes Under Various Stimuli," <i>Immunobiol.</i> , Vol. 171, pp. 302-310 (1986)
C56	Garrigues, et al., "The Melanoma Proteoglycan: Restricted Expression on Microspikes, a Specific Microdomain of the Cell Surface," <i>J. Cell Biol.</i> Vol. 103, pp 1699-1710 (1986)
C57	Gasco, et al., "In Vitro Permeation of Azelaic Acid from Viscosized Microemulsions", <i>International Journal of Pharmaceutics</i> , 69, 193-196 (1991)
C58	Gasco, M. R., et al., "Long-acting Delivery Systems for Peptides: Reduced Plasma Testosterone Levels in Male Rats after a Single Injection:, <i>Intl. J. of Pharmaceut.</i> , 62 119-123 (1990)
C59	Glagov, et al., "Compensatory Enlargement of Human Atherosclerotic Coronary Arteries," <i>New England J. of Med.</i> , Vol. 316 No. 22, p. 1371-1375 (1987)
C60	Goldman, et al., "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to Horseradish Peroxidase," <i>Atherosclerosis</i> , Vol. 65, pp. 215-225 (1987)
C61	Grainger, et al., "Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor-like activity from serum," <i>Cardiovascular Research</i> , Vol 27, pp. 2238-47 (1993)
C62	Grainger, et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells in Culture by Inducing Production of Transforming Growth Factor β ," <i>Biochem J.</i> Vol. 294, pp. 109-112 (1993)
C63	Grainger, et al., A Large Accumulation of Non-Muscle Myosin Occurs at First Entry into M Phase in Rat Vascular Smooth-Muscle Cells," <i>Biochem. J.</i> Vol. 277, pp. 145-151 (1991)
C64	Grainger, et al., Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth Muscle Cells," <i>Biochem. J.</i> Vol. 283, p. 403-408 (1992)
C65	Gregory, et al. "Effects of Treatment with Cyclosporine, FK 506, Rapamycin, Mycophenolic Acid, or Deoxyspergualin on Vascular Muscle Proliferation <i>in Vivo</i> ," <i>Transplantation Proceedings</i> , 25:770-771 (1993)
C66	Hanke, et al., Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-Weight Heparin," <i>Circulation</i> , Vol 85, No. 4, pp. 1548-56 (1992)
C67	Harpel, et al., "Plasmin Catalyzes Binding of Lipoprotein (α) to Immobilized Fibrinogen and Fibrin," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86, pp. 3847-3851 (1989)
C68	Heldin, et al., "Demonstration of an Antibody Against Platelet-derived Growth Factor," <i>Experimental Cell Research</i> , Vol. 136, pp. 255-261 (1981)
C69	Heller, et al., "Preparation of Polyacetals by the Reaction of Divinyl Ethers and Polyols," <i>J. of Polymer Science: Polymer Letters Edition</i> , Vol. 18, pp. 298-297 (1980)
C70	Henriksson, et al., "Hormonal Regulation of Serum Lp (α) Levels; <i>J. Clin. Invest.</i> Vol. 89, p. 1166-1171 (1992)
C71	Hermans et al., "Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet"" <i>American Heart Journal</i> , 122 (1) Part, 1, 171-187, 1991
C72	Hirata et al., "Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate". <i>Arthritis and Rheumatism</i> , 32(9): 1065-1073, 1989
C73	Hoff, et al., "Modification of Low Density Lipoprotein with 4-Hydroxynonenal Induces Uptake by Macrophages," <i>Arteriosclerosis</i> , Vol. 9, No. 4, pp. 538-549 (1989)
C74	Hoffman, et al., "Enhancement of the Antiproliferative Effect of <i>cis</i> -Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C," <i>Int. J. Cancer</i> , Vol. 42, pp. 382-388 (1988)
C75	Holland, et al., "Atherogenic Levels of Low-density Lipoprotein Increase Endocytotic Activity in Cultured Human Endothelial Cells," <i>Amer. J. of Pathology</i> , Vol. 140, No. 3, pp. 551-558 (1992)
C76	Hwang et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1 and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture." <i>Exp. Cell Res.</i> , 200, 358-360 (1992)
C77	Jampel et al., "In vitro release of hydrophobic drugs from polyanhydride disks". <i>Ophthal Surg</i> , 23 (11):676-680, 1991
C78	Jarvis, et al., "Allelopathic Agents from Parthenium hysterophorus and Baccharis megapotamica," <i>Chemistry of Alleopathy</i> , pp. 149-159 (1985)
C79	Jarvis, et al., "Macrocyclic and Other Novel Trichothecenes: Their Structure, Synthesis, and Biological Significance," <i>Acc. Chem. Res.</i> 15 pp. 338-395 (1982)
C80	Johnson, et al., "Coronary Atherectomy: Light Microscopic and Immunochemical Study of Excised Tissues," <i>Supp. II Circulation</i> , Vol. 78, No. 4, p. II-82 (1988)
C81	Jordan, V. Craig, "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to Clinical Trials," <i>Hormones, Cell Biol. and Cancer: Perspectives and Potentials</i> , pp. 105-123 (1988)
C82	Jung, S.M., et al., "Platelet Cytoskeletal Protein Distributions in Two Triton-Insoluble Fractions and How They are Affected by Stimulants and Reagents that Modify Cytoskeletal Protein Interactions" <i>Thrombosis Research</i> ,




	50 775-787 (1988)
C83	Kambic, <i>et al.</i> , "Biomaterials in Artificial Organs," <i>Chemical & Engineering News</i> , pp. 31-48 (1986)
C84	Kemp <i>et al.</i> , "The <i>Id</i> Gene is Activated by Serum But is Not Required for De-differentiation in Rat Vascular Smooth Muscle Cells," <i>Biochem. J.</i> (Great Britain), Vol. 277, pp. 285-288 (1991)
C85	Knabbe, C., <i>et al.</i> , "Evidence That Transforming Growth Factor beta is a Hormonally Regulated Negative Growth Factor in Human Breast Cancer Cells" <i>Cell</i> , 48 417-428
C86	Koff, <i>et al.</i> , "Negative Regulation of G1 in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGF- β ," <i>Science</i> , Vol. 260, pp. 536-538 (1993)
C87	Kovach, <i>et al.</i> , "Serial Intravascular Ultrasound Studies Indicate That Chronic Recoil Is An Important Mechanism Of Restenosis Following Transcatheter Therapy," <i>JACC</i> Vol. 484A, Abstract 835-3 (1993)
C88	LaFont, <i>et al.</i> , "Post-angioplasty Restenosis In The Atherosclerotic Rabbit: Proliferative Response Or Chronic Constriction?," <i>Circulation</i> , Vol. 88, I-521, Abstract 2806 (1993)
C89	Lambert <i>et al.</i> , "A new method for arterial drug delivery via removable stent". <i>JACC</i> , 21(2):483A, #834-2, 1992
C90	Lambert, <i>et al.</i> , "Local Drug Delivery Catheters: Functional Comparison of Porous and Microporous Designs," <i>Coronary Artery Disease</i> , Vol. 4, No. 5, pp. 469-475 (1993)
C91	Lefer, Allen M., "Role of Transforming Growth Factor β in Cardioprotection of the Ischemic-Reperfused Myocardium," <i>Growth Factors and the Cardiovascular System</i> , Chapter 14 (Cummins, P. ed.), Kluwer Academic Publishers, pp. 249-260 (1993)
C92	Lefer, <i>et al.</i> , "Mechanism of the Cardioprotective Effect of Transforming Growth Factor β_1 , in Feline Myocardial Ischemia and Reperfusion," <i>PNAS (USA)</i> , Vol. 90, pp. 1018-22 (1993)
C93	Lefer, <i>et al.</i> , "Mediation of Cardioprotection by Transforming Growth Factor- β ," <i>Science</i> , Vol. 249, pp. 61-64 (1990)
C94	Levy, "Drug Release from Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", <i>Intl. J. Pharmaceut.</i> , 66, 29-37 (1990)
C95	Levy, <i>et al.</i> , "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants," <i>Chemical Abstracts</i> , 121, 580: Abstract No. 263625g (1994)
C96	Li, <i>et al.</i> , "Structure and Dynamics of Microemulsions which Mimic the Lipid Phase of Low-Density Lipoproteins", <i>Biochimica et Biophysica Acta</i> , 1042, 42-50 (1990)
C97	Liaw, <i>et al.</i> , "Osteopontin Promotes Vascular Cell Adhesion and Spreading and Is Chemotactic for Smooth Muscle Cells <i>In Vitro</i> ," <i>Cir. Res.</i> Vol. 74, No. 2, pp. 214-224 (1994)
C98	Lin, <i>et al.</i> , "Expression Cloning of the TGF- β Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase," <i>Cell</i> , Vol. 68, pp. 775-785 (1992)
C99	Linn, <i>et al.</i> , "Microemulsion for Intradermal Delivery of Cetyl Alcohol and Octyl Dimethyl Paba", <i>Drug Development and Industrial Pharmacy</i> , 16, 899-920
C100	Lipski, <i>et al.</i> , "Cytochalasin B: Preparation, Analysis in Tissue Extracts, and Pharmacokinetics After Intraperitoneal Bolus Administration In Mice," <i>Analytical Biochem.</i> , Vol. 161, pp. 332-340 (1987)
C101	Liu, <i>et al.</i> , "Restenosis After Coronary Angioplasty - Potential Biologic Determinants and Role of Intimal Hyperplasia," <i>Circulation</i> , Vol. 79, No. 6, pp. 1374-87 (1989)
C102	Love, <i>et al.</i> , "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women," <i>Annals of Internal Medicine</i> , Vol. 115, No. 11, pp. 860-864 (1991)
C103	Love, <i>et al.</i> , "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients with Node-Negative Breast Cancer," <i>J. of the National Cancer Institute</i> , Vol. 82, No. 16, pp. 1327-32 (1990)
C104	Maione, Theodore E. and Sharpe, Richard J. "Development of angiogenesis inhibitors for clinical applications" <i>TIPS</i> - Nov. 1990 [Vol. 11]
C105	Malcolmson, <i>et al.</i> , "A Comparison Between Nonionic Micelles and Microemulsions as a Means of Incorporating the Poorly Water Soluble Drug Diazepam", <i>J. Pharm. Pharmacol.</i> , 42 6p, (1990)
C106	Manasek, <i>et al.</i> , "The Sensitivity of Developing Cardiac Myofibrils to Cytochalasin-B," <i>PNAS (USA)</i> , Vol. 69, No. 2, pp. 308-312 (1972)
C107	Mang, Tien-Dung Duc, "Distribution to Normal and Tumor Tissues of Cytochalasin B After Intravenous Administration in Mice," Thesis Submitted for Honors B.S. in Biology, Syracuse University
C108	Massagué, Joan, "The Transforming Growth Factor-B; Family", <i>Annu. Rev. Cell Biol.</i> Vol. 6, pp. 597-641 (1990)
C109	McCaffrey, <i>et al.</i> , "Transforming Growth Factor; β Activity is Potentiated by Heparin Via Dissociation of the Transforming Growth Fact--Macroglobulin Inactive Complex," <i>The J. of Cell Biology</i> , Vol. 109, pp. 441-448 (1989)
C110	McCarroll, <i>et al.</i> , "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor- β (TGF- β) by Endothelial Cells in Culture," <i>Clin. Chem.</i> Vol. 36, No. 6, pp. 1152-(1990)-Abstract No. 0934-
C111	McCormick, <i>et al.</i> , "Retinoid-Tamoxifen Interaction in Mammary Cancer Chemoprevention," <i>Carcinogenesis</i> , Vol. 7, No. 2, pp. 193-196 (1986)
C112	McDonald, <i>et al.</i> , "Fatal Myocardial Infarction in the Scottish Adjuvant Tamoxifen Trial," <i>BMJ</i> , Vol. 303 pp. 435-437 (1991)



C113	McLean, <i>et al.</i> , "cDNA Sequence of Human Apolipoprotein(α) is Homologous to Plasminogen," <i>Nature</i> , Vol. 330, No. 643, pp. 132-137 (1987)
C114	McQuiggan, James Daniel: "Tissue Distribution of Cytochalasin B After Intraperitoneal Bolus and Microencapsulated Injection in Mice and its Effect on β-N-Acetylglucosaminidase Activity in Cultured B16-BL6 Melanoma Cells," Thesis Submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology in the Graduate School of Syracuse University, published Syracuse University, Biology Dept. (1988)
C115	Merrilees, <i>et al.</i> , "Synthesis of TGF-β ₁ by Vascular Endothelial Cells is Correlated with Cell Spreading," <i>J. Vasc. Res.</i> , Vol. 29, pp. 376-384 (1992)
C116	Middlebrook, <i>et al.</i> , "Specific Association of T-2 Toxin with Mammalian Cells," <i>Biochem. Pharmacology</i> , Vol. 38, No. 18, pp. 3093-3102 (1989)
C117	More <i>et al.</i> , "A Targeted Antithrombotic Conjugate with Antiplatelet and Fibrinolytic Properties which reduces in vivo Thrombus Formation", <i>Cardiovascular Research</i> , 27, 2200-2204 (1993).
C118	Morisaki, <i>et al.</i> , "Effects of Transforming Growth Factor β on Growth of Aortic Smooth Muscle Cells," <i>Atherosclerosis</i> , Vol. 88, pp. 227-234 (1991)
C119	Moses and Langer "Inhibitors of angiogenesis". <i>Bio/Technology</i> . 9:630-634, 1991
C120	Nabel, "Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall", <i>Science</i> , 244, 1342-1344 (1983)
C121	Naito, <i>et al.</i> , "Vascular Endothelial Cell Migration <i>In Vitro</i> Roles of Cyclic Nucleotides, Calcium Ion and Cytoskeletal System," <i>Artery</i> , Vol. 17(1), pp. 21-31 (1989)
C122	Nakao, <i>et al.</i> , "Calcium Dependency of Aortic Smooth Muscle Cell Migration Induced by 12-L-Hydroxy-5,8,10,14-eicosatetraenoic Acid," <i>Atherosclerosis</i> , Vol. 46, pp. 309-319 (1983)
C123	Nikol, <i>et al.</i> , "Expression of Transforming Growth Factor β ₁ is Increased in Human Vascular Restenosis Lesions," <i>J. Clin. Invest.</i> , Vol. 90, pp. 1582-92 (1992)
C124	Nunes, <i>et al.</i> , "Vitamins C and E Improve the Response to Coronary Balloon Injury In the Pig: Effect of Vascular Remodeling," <i>Circulation</i> , Vol. 88, No. 4, Part 2, p. I-372 (1993)
C125	O'Brien, <i>et al.</i> , "Osteopontin mRNA and Protein are Overexpressed in Human Coronary Atherectomy Specimens: Clues to Lesion Calcification," <i>Cir.</i> Vol. 88, p. I-619, Abstracts from the 66 th Scientific Sessions (1993)
C126	O'Connor-McCourt, <i>et al.</i> , "Latent Transforming Growth Factor β in Serum: A Specific Complex with 2-Macroglobulin," <i>The Journal of biological Chemistry</i> , Vol. 262, No. 29, pp. 14090-14099 (1987)
C127	Ohmi, <i>et al.</i> , "Effect of K252a, A Protein Kinase Inhibitor, on the Proliferation of Vascular Smooth Muscle Cells," <i>Biochemical and Biophysical Research Communications</i> , Vol. 173, No. 3, p. 976-981 (1990)
C128	O-Keefe Jr. <i>et al.</i> , "Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty". <i>JACC</i> , 19(7): 1597-1600, 1992
C129	Oliveira, <i>et al.</i> , "Isolation and Characterization of Smooth Muscle Cell Membranes," <i>Biochimica et Biophysica Acta</i> . Vol. 332, pp. 221-232 (1974)
C130	Osborne, <i>et al.</i> , "Microemulsions as Topical Drug Delivery Vehicles: In Vitro Transdermal Studies of a Model Hydrophilic Drug", <i>J. Pharm. Pharmacol.</i> , 43, 451-454 (1991).
C131	Osipow, "Transparent Emulsion" <i>J. Soc. Cosmetic Chemists</i> , 277-285 (1963).
C132	Palmaz <i>et al.</i> , "Intravascular Stents", <i>Advances in Vascular Surgery</i> , 1, 107-135 (1993).
C133	Pardee, <i>et al.</i> , "Control of Cell Proliferation," <i>Cancer</i> , Vol. 39, pp. 2747-54 (June Supplement 1977)
C134	Pathak, <i>et al.</i> , "Enhanced Stability of Physostigmine Salicylate in Submicron o/w Emulsion", <i>International Journal of Pharmaceutics</i> , 65, 1690175 (1990)
C135	Podzimek, <i>et al.</i> , "O/W Microemulsions", <i>J. Dispersion Science and Technology</i> , I, 341-359 (1980)
C136	Popma, <i>et al.</i> , "Factors Influencing Restenosis After Coronary Angioplasty", <i>The Amer. J. of Med.</i> Vol. 88, pp. 1-16N - 1-24N (1990)
C137	Post, <i>et al.</i> , "Restenosis Is Partly Due To Intimal Hyperplasia And Partly To Remodeling Of The Injured Arterial Wall," <i>European Heart J.</i> , Vol. 14, p. 201, Abstract P1164 (1993)
C138	Post, <i>et al.</i> , "Which Part Of The Angiographic Diameter Reduction After Balloon Dilation Is Due To Intimal Hyperplasia?", <i>JACC</i> , Vol. 21, 36A, Abstract, 851-95 (1993)
C139	Pouton, C.W., "Self-Emulsifying Drug Delivery Systems: Assessment of the Efficiency of Emulsification", <i>International Journal of Pharmaceutics</i> , 27, 335-348, (1985)
C140	Powell <i>et al.</i> , "Suppression of the Vascular Response to Injury: The Role of Angiotensin-Converting Enzyme Inhibitors", <i>JACC</i> , 17, 137B-142B (1991).
C141	Rauterberg, <i>et al.</i> , "Collagens in Atherosclerotic Vessel Wall Lesions," <i>Current Topics in Pathology</i> , Vol. 87, pp. 163-192 (1993)
C142	Reid, <i>et al.</i> , "Fragmentation of DNA in P388D ₁ Macrophages Exposed to Oxidized Low-density Lipoprotein," <i>FEBS Letters</i> , Vol. 332, No. 3, pp. 218-220 (1993)
C143	Ross, <i>et al.</i> , "Chronic Inflammation, PDGF, TGF, and Smooth Muscle Proliferation, Abstracts from the 20 th

	Annual Meeting of the Keystone Symposia on Molecular Biology, Session on Molecular Mechanisms of Vascular Disease, <i>J. Cell Biochem.</i> S15C, Abstract No. G006, p. 96 (1991)
C144	Ross, Russell, "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s, <i>Nature</i> , Vol. 362, pp. 801-09 (1993)
C145	Sagitani, et al., "Microemulsion Systems with a Nonionic Cosurfant" <i>J. Dispersion Science and Technology</i> , 1 (2), 151-164 (1980)
C146	Sanders, et al., "Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(d,l-lactide-co-glycolide) Microspheres," <i>Journal of Pharmaceutical Sciences</i> , Vol. 73, No. 9, pp. 1294-1297 (1984)
C147	Schatz, "A View of Vascular Stents", <i>Circulation</i> , 79 445-457 (1989)
C148	Schlingemann, et al., Expression of the High Molecular Weight Melanoma-Associated Antigen by Pericytes During Angiogenesis in Tumors and in Healing Wounds," <i>Amer. J. Pathology</i> , Vol. 136, No. 6, pp. 1393-1405 (1990)
C149	Schneiderman, et al., "Increased Type I Plasminogen Activator Inhibitor Gene Expression in Atherosclerotic Human Arteries," <i>PNAS (USA)</i> , Vol. 89, pp. 6998-7002 (1992)
C150	Schwartz, et al., "Maintenance of Integrity in Aortic Endothelium," <i>Fed. Proc.</i> , Vol. 39, No. 9, pp. 2618-25 (1980)
C151	Schwartz, et al., "Restenosis After Balloon Angioplasty - A Practical Proliferative Model in Porcine Coronary Arteries, <i>Circulation</i> , Vol. 82, No. 6, pp. 2190-2200 (1990)
C152	Schwartz, et al., "The Restenosis Paradigm Revisited: An Alternative Proposal for Cellular Mechanisms," <i>JACC</i> , Vol. 20, No. 5, pp. 1284-93 (1992)
C153	Shanahan, et al., "Isolation of Gene Markers of Differentiated and Proliferating Vascular Smooth Muscle Cells," <i>Circulation Research</i> , Vol. 73, No. 1 (1993)
C154	Shewmon, et al., "Tamoxifen Lowers Lp(a) in Males with Heart Disease," <i>Supplement I Cir.</i> , Vol. 86, No. 4, p. 1345 (1992)
C155	Shoji, et al., "Enhancement of Anti-Inflammatory Effects of Biphenylacetic Acid by its Incorporation into Lipid Microspheres," <i>J. Pharm. Pharmacol.</i> 38:118-121 (1985)
C156	Simpson, J.B., et al., "Percutaneous Coronary Atherectomy", <i>Circulation</i> , 78, 61 st Scientific Session, Abstract No. 0326, p. II-82, (1988)
C157	Singh, et al., "Phylogenetic Analysis of Platelet-derived Growth Factor by Radio-Receptor Assay," <i>The Journal of Cell Biology</i> , Vol. 95, pp. 667-671 (1982)
C158	Snow, et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells," <i>American J. of Pathology</i> , Vol. 137, No. 2 (1990)
C159	Speir et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis", <i>Science</i> , 265, 391-394 (1994)
C160	Steele, P.M. et al., "Balloon Angioplasty -- Nature History of the Pathophysiological Response to Injury in a Pig Model", <i>Circulation Research</i> , 57 105-112 (1985)
C161	Streuli, et al., "Extracellular Matrix Regulators Expression of the TGF- β 1 Gene," <i>The J. of Cell Biol.</i> Vol. 120, No. 1, pp. 253-260 (1993)
C162	Suckling, Keith E., "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent Literature," <i>Biochem. Society Transactions</i> , Vol. 21, pp. 660-662 (1993)
C163	Tamm, Ch. Basel, "The Antibiotic Complex of the Verrucarins and Roridins," <i>Fortschr. Chem. Org. Naturst.</i> , 31:65 117 (1974)
C164	Tang et al., "Regression of collagen-induced arthritis with taxol, a microtubule stabilizer". <i>Arthritis and Rheumatism</i> , 36 (9) Suppl.:S45, 1993
C165	Tice, et al., "Biodegradable controlled-release parental systems" <i>Pharmaceutical Technology</i> , 26-35 (1984)
C166	Topol, Eric J., "The Restenosis "Antitheory", <i>Mayo Clinic Proc.</i> Vol. 68, pp. 88-90 (1993)
C167	Vanhoutte, P.M., "Hypercholesterolemia, Atherosclerosis And Release Of Endothelium-Derived Relaxing Factor By Aggregating Platelets," <i>European Heart J.</i> Vol. 12, Supplement E. pp. 25-32 (1991)
C168	Vargas, et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery," <i>Br. J. Pharmacol.</i> , Vol. 109, pp. 612-617 (1993)
C169	Vijayagopal, et al., "Human Monocyte-Derived Macrophages Bind Low-Density-Lipoprotein-Proteoglycan Complexes by a Receptor Different from the Low-Density-Lipoprotein Receptor," <i>Biochem. J.</i> , Vol. 289, pp. 837-844 (1993) (GB)
C170	Vijayagopal, et al., "Lipoprotein-Proteoglycan Complexes Induce Continued Cholesteryl Ester Accumulation in Foam Cells from Rabbit Atherosclerotic Lesions," <i>J. Clin. Invest.</i> Vol. 91, pp. 1011-18 (1993)
C171	Voisard, et al., "The In-Vitro Effect of Antineoplastic Agents on Proliferative Activity and Cytoskeletal Components of Plaque-derived Smooth-muscle Cells from Human Coronary Arteries," <i>Coronary Artery Disease</i> , 4:935-942 (1993)
C172	Voisard, R., et al., "Search for new strategies for prevention of restenosis after angioplasty: the effect of cytostatic drugs on cell migration of re-stenosing human plaques cells in vitro". <i>Vasa Suppl.</i> 1992; 35: 132-3 [Article in German]



C173	Wakefield, <i>et al.</i> , "Latent Transforming Growth Factor β from Human Platelets: A High Molecular Weight Complex Containing Precursor Sequences," <i>The Journal of Biological Chemistry</i> , Vol. 263, No. 16, pp. 7646-7654 (1988)
C174	Wakefield, <i>et al.</i> , "Recombinant Latent Transforming Growth Factor I Has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor, I, and a Different Tissue Distribution," <i>The Journal of Clinical Investigation, Inc.</i> , Vol. 86, pp. 1976-1984 (1990)
C175	Weissberg, <i>et al.</i> , "Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation," <i>Cardiovascular Res.</i> , Vol. 27, pp. 1191-98 (1993)
C176	Weissberg, <i>et al.</i> , "The Endothelin Peptides ET-1, ET-2, ET-3 and Sarafotoxin S6b are Comitogenic with Platelet-Derived Growth Factor for Vascular Smooth Muscle Cells," <i>Atherosclerosis</i> , Vol. 85, pp. 257-262 (1990)
C177	Weissberg, <i>et al.</i> , Effects of TGFB on Vascular Smooth Muscle Cell Growth, <i>Growth Factors and the Cardiovascular System</i> , (Cummins, P.ed), Kluwer Academic Publishers, p. 189-205 (1993)
C178	Wight, <i>et al.</i> , "Proteoglycans Structure and Function," <i>Cell Biol. of Extracellular Matrix</i> , Second Edition, edited by Elizabeth D. Hay, PLENUM PRESS, NEW YORK CHAPTER 2, pp. 45-78 (1991)
C179	Wight, <i>et al.</i> , "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation," <i>Current Opinion in Cell Biol.</i> Vol. 4, pp. 793-801 (1992)
C180	Wight, Thomas N., "Cell Biology of Arterial Proteoglycans," <i>Arteriosclerosis</i> , Vol. 9, No. 1., pp. 1-20 (1989)
C181	Wilensky, <i>et al.</i> , "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Delivery Strategy Following Angioplasty," <i>American Heart Journal</i> , Vol. 122, No. 4, pp. 1136-1140 (1991)
C182	Wolinsky, <i>et al.</i> , "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery," <i>JACC</i> , Vol. 15, No. 2, pp. 475-81 (1990)
C183	Zuckerman, <i>et al.</i> , "Cytokine Regulation of Macrophage apo E Secretion: Opposing Effects of GM-CSF and TGF- β ," <i>Atherosclerosis</i> , Vol. 96, pp. 203-214 (1992)
C184	Zukerman, <i>et al.</i> , "Exogenous Glucocorticoids Increase Macrophage Secretion of E by Cholesterol-Independent Pathways," <i>Atherosclerosis</i> , Vol. 103, pp. 43-54 (1993)

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	